Net sales and profits declined year-over-year due to lower new drug sales and NHI price revisions, despite growth in Beova and generics. Operating profit and net income fell sharply, but full-year forecasts and dividend plans remain unchanged.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.